论文部分内容阅读
目的探讨沙利度胺与泼尼松片分别联合来氟米特治疗对系统性红斑狼疮(SLE)血清B细胞活化因子(BAFF)和白细胞介素-21(IL-21)水平变化及治疗的临床疗效。方法 180例符合1997年美国风湿病协会制定的诊断标准的SLE患者,随机分为观察组和对照组,各90例。观察组口服沙利度胺,对照组采用口服泼尼松片。两组均同时按照来氟米特的用药标准注射来氟米特。治疗3个月后检测两组患者的血清BAFF和IL-21水平。结果观察组患者血清中BAFF和IL-21值分别为(10.2±3.1)μg/L和(817±324)ng/L,对照组患者血清中BAFF和IL-21值分别为(13.5±2.9)μg/L和(986±337)ng/L。观察组患者的血清中BAFF和IL-21值显著低于对照组,差异有统计学意义(P<0.05)。结论采用沙利度胺联合来氟米特治疗系统性红斑狼疮的效果优于采用泼尼松片联合来氟米特治疗的效果,在临床上值得推广使用。
Objective To investigate the effects of thalidomide and prednisone tablets combined with leflunomide on serum levels of B-cell activator (BAFF) and interleukin-21 (IL-21) in patients with systemic lupus erythematosus (SLE) Clinical efficacy. Methods One hundred and eighty patients with SLE who met the diagnostic criteria set by American Rheumatism Association in 1997 were randomly divided into observation group and control group, with 90 cases each. The observation group oral thalidomide, the control group oral prednisone tablets. Both groups were given leflunomide at the same time as leflunomide. Three months after treatment, serum BAFF and IL-21 levels were measured in both groups. Results The serum levels of BAFF and IL-21 in the observation group were (10.2 ± 3.1) μg / L and (817 ± 324) ng / L, respectively. The BAFF and IL-21 levels in the control group were (13.5 ± 2.9) μg / L and (986 ± 337) ng / L. The serum levels of BAFF and IL-21 in the observation group were significantly lower than those in the control group (P <0.05). Conclusion The effect of thalidomide combined with leflunomide in the treatment of systemic lupus erythematosus is superior to the effect of prednisone and leflunomide, which is worthy of promotion in clinic.